Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.42 |
| ▸ | NMT2 | O60551 | 6/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23105910 | 1.00 | NMT1 (0.42) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL23106148 | 0.94 | FAP (0.37) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23106109 | 0.93 | PTGS1 (0.39) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23106064 | 0.92 | NPY4R (0.43) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23105993 | 0.92 | NPY5R (0.39) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL23105990 | 0.92 | NPY5R (0.39) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL23105973 | 0.92 | PTGS1 (0.41) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23106076 | 0.92 | NPY4R (0.44) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23106024 | 0.92 | PTGS1 (0.39) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL23106144 | 0.91 | PTGS1 (0.37) | NMT1NMT2NPY5RNPY1RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | NMT1 3078/4885NMT2 2380/4885TLR2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.